{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:16:57Z","timestamp":1792588617095,"version":"4.5.0"},"reference-count":23,"publisher":"Rockefeller University Press","issue":"9","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.rupress.org\/terms\/"},{"start":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:00:00Z","timestamp":1615075200000},"content-version":"vor","delay-in-days":261,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA049605"],"award-info":[{"award-number":["P01 CA049605"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"The Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["LLS TRP-6010-14"],"award-info":[{"award-number":["LLS TRP-6010-14"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,7]]},"abstract":"<jats:p>Here, we report on the results of a phase I\/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of \u22651 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89%) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40% of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe.<\/jats:p>","DOI":"10.1084\/jem.20191712","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T12:59:33Z","timestamp":1592571573000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I\/II trial"],"prefix":"10.1084","volume":"217","author":[{"given":"Matthew J.","family":"Frank","sequence":"first","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9061-7351","authenticated-orcid":true,"given":"Michael S.","family":"Khodadoust","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra K.","family":"Czerwinski","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-9250","authenticated-orcid":true,"given":"Ole A.W.","family":"Haabeth","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, Edmonton, Alberta, Canada 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":true,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":true,"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-2965","authenticated-orcid":true,"given":"Lauren S.","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil A.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-6785","authenticated-orcid":true,"given":"Ginna G.","family":"Laport","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett H.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1661-7334","authenticated-orcid":true,"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8902-8189","authenticated-orcid":true,"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Stanford University Healthcare, Stanford, CA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9778-3747","authenticated-orcid":true,"given":"Kevin","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Faham","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies, Seattle, WA 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Holliston","family":"Moore","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4765-7013","authenticated-orcid":true,"given":"Destiny L.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2062-2854","authenticated-orcid":true,"given":"Irene L.","family":"Wapnir","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stanford University Healthcare, Stanford, CA 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-0650","authenticated-orcid":true,"given":"Ronald","family":"Levy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Stanford University, Stanford, CA 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"2023072617474567600_bib1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0301-472X(02)00807-X","article-title":"Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1\/JH rearrangements in mantle cell lymphoma","volume":"30","author":"Andersen","year":"2002","journal-title":"Exp. Hematol"},{"key":"2023072617474567600_bib2","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"2023072617474567600_bib3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"2023072617474567600_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression Models and Life-Tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Series B Stat. Methodol"},{"key":"2023072617474567600_bib5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"2023072617474567600_bib6","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"2023072617474567600_bib7","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"2023072617474567600_bib8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"2023072617474567600_bib9","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"2023072617474567600_bib10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood-2010-06-288456","article-title":"A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors","volume":"117","author":"Goldstein","year":"2011","journal-title":"Blood"},{"key":"2023072617474567600_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.69.1.81","article-title":"CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens","volume":"69","author":"Jahrsd\u00f6rfer","year":"2001","journal-title":"J. Leukoc. Biol"},{"key":"2023072617474567600_bib12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"key":"2023072617474567600_bib13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood"},{"key":"2023072617474567600_bib14","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"2023072617474567600_bib15","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"2023072617474567600_bib16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"2023072617474567600_bib17","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.4049\/jimmunol.179.4.2493","article-title":"Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself","volume":"179","author":"Li","year":"2007","journal-title":"J. Immunol"},{"key":"2023072617474567600_bib18","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/2159-8290.CD-19-0391","article-title":"Antitumor T-cell homeostatic activation is uncoupled from homeostatic inhibition by checkpoint blockade","volume":"9","author":"Marshall","year":"2019","journal-title":"Cancer Discov"},{"key":"2023072617474567600_bib19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nature14138","article-title":"Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9","volume":"520","author":"Ohto","year":"2015","journal-title":"Nature"},{"key":"2023072617474567600_bib20","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"2023072617474567600_bib21","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"2023072617474567600_bib22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023072617474567600_bib23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","article-title":"Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities","volume":"110","author":"Wolfl","year":"2007","journal-title":"Blood"}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20191712\/1780506\/jem_20191712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20191712\/1780506\/jem_20191712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T11:43:31Z","timestamp":1722858211000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/217\/9\/e20191712\/151871\/Autologous-tumor-cell-vaccine-induces-antitumor-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,7]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20191712","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"article-number":"e20191712"}}